|
|
|
|
|
|
|
10.06.26 - 17:30
|
Here′s Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher (Zacks)
|
|
|
PDS Biotechnology (PDSB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term....
|
|
|
|
|
|
|
|
|
|
|
17.04.26 - 19:18
|
Weekly Buzz: FDA Okays Travere Therapeutics, Royal Philips; Rejects Replimune; American Industrial Partners Snaps Up Avanos Medical; PDS Biotechnology, Hoth Therapeutics, Spyre Therapeutics, Paces Trials (AFX)
|
|
|
INDIANAPOLIS (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S., Taiwan, and Europe, alongside FDA rejections, collaborations, acquisitions, and positive data......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24.03.26 - 21:09
|
PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results (GlobeNewswire EN)
|
|
|
PRINCETON, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call and webcast to report financial results for the quarter and year ended December 31, 2025, and will provide a clinical programs and corporate update, on Monday, March 30, 2026 at 8:00 am Eastern Time....
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
